Efficacy and safety of ezetimibe plus atorvastatin therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of ezetimibe plus atorvastatin therapy

Published:2014-08-01 Issue:4 Volume:9 Page:441-470
ISSN:1758-4299
Container-title:Clinical Lipidology
language:en
Short-container-title:Clinical Lipidology

Author:

Foody JoAnne M¹,Toth Peter P²³,Tershakovec Andrew M⁴,Musliner Thomas⁴,Tomassini Joanne E⁴,Lowe Robert S⁴,Neff David R⁴,Davis Harry R⁴

Affiliation:

1. Cardiovascular Wellness Program, Brigham and Women’s Hospital, PB-136, Boston, MA 02115, USA

2. CGH Medical Center, Sterling, IL 61081, USA

3. University of Illinois College of Medicine, Peoria, IL 61605, USA

4. Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, USA

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.2217/clp.14.36

Reference220 articles.

1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010). •• Largest meta-analysis of 26 randomized controlled statin trials, including intensive treatment, showing that the magnitude of LDL lowering is related to the reduction of cardiovascular events.

2. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).

3. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46(10), 1855–1862 (2005). • Meta-analysis of 18 intervention trials showing the relationship between statin and nonstatin lipid-lowering therapies with cardiovascular risk reduction.

4. Anderson TJ, Gregoire J, Hegele RA et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29(2), 151–167 (2013).

5. Teramoto T, Sasaki J, Ishibashi S et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 Version. J. Atheroscler. Thromb. 20(6), 517–523 (2013).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress in the Clinical Treatment of Familial Hypercholesterolemia;Current Medicinal Chemistry;2024-03

2. Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: A retrospective cohort study;Preventive Medicine Reports;2023-08

3. Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study;Cardiovascular Therapeutics;2022-05-24

4. Synthesis of spirooxindole analogues from 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde;Synthetic Communications;2019-12-27

5. Ezetimibe in the treatment of hypercholesterolaemia;Interní medicína pro praxi;2019-05-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3